Castle Biosciences, Inc.

Castle Biosciences Beats on EPS, Stock Up 0.42%

Castle Biosciences reported a narrower-than-expected loss per share, which contributed to a slight increase in stock price. However, there was no revenue reported or guidance provided, leaving investors with limited insights into future performance. The stock's modest rise suggests that investors reacted positively to the EPS surprise despite the lack of additional information.